/
IMNM
$19.87-$0.04 (-0.20%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.3B
113M shares
52-week range
$7.96 – $27.65
60% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$2.62
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $14.0M | $9.0M | $6.9M |
| Cost of revenue | $521.0K | $615.0K | $755.0K | $0 | $0 | $0 | $0 | $3.0M |
| Gross profit | −$521.0K | −$615.0K | −$755.0K | $0 | $0 | $14.0M | $9.0M | $4.0M |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 57.4% |
| R&D | $6.9M | $8.8M | $6.7M | $14.1M | $23.3M | $23.1M | $129.5M | $174.3M |
| Operating income | −$7.7M | −$10.3M | −$12.3M | −$25.2M | −$36.9M | −$109.5M | −$305.8M | −$214.1M |
| EBITDA | −$7.2M | −$9.7M | −$17.0M | −$23.9M | −$36.3M | −$28.0M | −$151.4M | −$209.4M |
| Net income | −$7.8M | −$10.6M | −$17.8M | −$24.7M | −$36.9M | −$106.8M | −$293.0M | −$212.4M |
| Net margin | — | — | — | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (diluted) | -7.18 | -1.84 | -1.69 | -2.14 | -3.09 | -5.38 | -5.00 | -2.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-2.14 | $-2.24–$-2.07 | 10 |
| 2027 | $59M | $-2.16 | $-2.54–$-1.81 | 9 |
| 2028 | $231M | $-1.12 | $-2.35–$-0.41 | 8 |
| 2029 | $403M | $-0.08 | $-0.19–$0.00 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.38
Price
$19.87
Implied downside
-63%
Peer comparison
Immunome, Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
www.immunome.com- Employees
- 177
- IPO / List date
- Oct 2, 2020
- HQ
- BOTHELL, WA
Held by traders on TradeandTell
No one on the platform currently holds IMNM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 68,902 | $1.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2007-12-19 | 1-for-1000reverse |
Recent trades on TradeandTell
No one on the platform has traded IMNM yet.
